Literature DB >> 7553496

The dilemma of hereditary prostate cancer.

J C Nickel.   

Abstract

The observation that a family history of prostate cancer significantly increases a man's risk of the disease (see pages 895 to 900 of this issue) highlights many of the ethical, emotional and pragmatic controversies in medical circles concerning the management of this common form of cancer. This editorial describes a patient's personal dilemma when he learns that his brother is dying of prostate cancer, a dilemma that illustrates the potential harms and benefits of early detection and treatment. Current evidence does not justify screening asymptomatic men for prostate cancer, but many Canadian physicians do practise early case detection for some patients with a high risk of the disease. Men with a family history of prostate cancer must be informed by their physicians about the known and unknown risks and benefits of early detection and treatment, before they undergo the cascade of diagnostic and therapeutic procedures associated with prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7553496      PMCID: PMC1487375     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  13 in total

1.  Case-control study of screening for prostatic cancer by digital rectal examinations.

Authors:  G D Friedman; R A Hiatt; C P Quesenberry; J V Selby
Journal:  Lancet       Date:  1991-06-22       Impact factor: 79.321

2.  Detection of prostate cancer.

Authors:  J P Collins
Journal:  CMAJ       Date:  1995-02-01       Impact factor: 8.262

3.  Morbidity and mortality following radical prostatectomy: a national analysis of Civilian Health and Medical Program of the Uniformed Services beneficiaries.

Authors:  S A Optenberg; B E Wojcik; I M Thompson
Journal:  J Urol       Date:  1995-06       Impact factor: 7.450

Review 4.  Report of the consensus workshop on screening and global strategy for prostate cancer.

Authors:  L J Denis; G P Murphy; F H Schröder
Journal:  Cancer       Date:  1995-03-01       Impact factor: 6.860

5.  High 10-year survival rate in patients with early, untreated prostatic cancer.

Authors:  J E Johansson; H O Adami; S O Andersson; R Bergström; L Holmberg; U B Krusemo
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

6.  Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles.

Authors:  D M Quinlan; J I Epstein; B S Carter; P C Walsh
Journal:  J Urol       Date:  1991-05       Impact factor: 7.450

7.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

Authors:  J E Oesterling; S J Jacobsen; C G Chute; H A Guess; C J Girman; L A Panser; M M Lieber
Journal:  JAMA       Date:  1993-08-18       Impact factor: 56.272

Review 8.  Prostate cancer. Radiation therapy for localized disease.

Authors:  M A Bagshaw; I D Kaplan; R C Cox
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860

Review 9.  The potential for hormonal prevention trials.

Authors:  L G Ford; O W Brawley; J A Perlman; S G Nayfield; K A Johnson; B S Kramer
Journal:  Cancer       Date:  1994-11-01       Impact factor: 6.860

10.  Screening for prostate cancer. A decision analytic view.

Authors:  M D Krahn; J E Mahoney; M H Eckman; J Trachtenberg; S G Pauker; A S Detsky
Journal:  JAMA       Date:  1994-09-14       Impact factor: 56.272

View more
  1 in total

1.  Hereditary prostate cancer.

Authors:  I Levy; A Coombs
Journal:  CMAJ       Date:  1996-02-01       Impact factor: 8.262

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.